DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Building BlocksBuilding Blocks
  4. /Heterocyclic ScaffoldsHeterocyclic Scaffolds
  5. /PiperidinesPiperidines
  6. /3-Piperidinecarboxamide, 1-(cyclopropylmethyl)-4-[[[5-(2,4-difluorophenyl)-3-isoxazolyl]carbonyl]amino]-N-[1-(2-pyrimidinyl)cyclopropyl]-, (3S,4S)-CAS 2178049-58-4
Chemical structure of CAS 2178049-58-4

3-Piperidinecarboxamide, 1-(cyclopropylmethyl)-4-[[[5-(2,4-difluorophenyl)-3-isoxazolyl]carbonyl]amino]-N-[1-(2-pyrimidinyl)cyclopropyl]-, (3S,4S)-

In Stock•Starting at $735 for 1 mg•Purity ≥ 99%
CAS No.2178049-58-4
MDL No.N/A
MFC27H28F2N6O3
MW522.50
InChI KeyIIDSHAJKXPUYSL-FPOVZHCZSA-N
CUSTOM SYNTHESIS

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg99%$735In Stock
5 mg99%$1824In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.2178049-58-4
Product Name3-Piperidinecarboxamide, 1-(cyclopropylmethyl)-4-[[[5-(2,4-difluorophenyl)-3-isoxazolyl]carbonyl]amino]-N-[1-(2-pyrimidinyl)cyclopropyl]-, (3S,4S)-
Heavy Atom Count38Rotatable Bond Count8
Atom Stereo Count2Bond Stereo Count0
HBA7HBD2
TPSA113.250 ŲCharge0
Exact Mass522.21910Complexity1341.59
pKa9.247XLogP3.046

Related Articles

Studies related to this compound and its mechanism of action

CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis.

Frontiers in pharmacology • Vol. 12 • 2021
PMID: 34803691PMC: PMC8602191DOI: 10.3389/fphar.2021.748740

Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie • Vol. 144 • 2021
PMID: 34794236DOI: 10.1016/j.biopha.2021.112363

ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • Vol. 35, Issue 3 • 2021
PMID: 33595155PMC: PMC12266320DOI: 10.1096/fj.202002465R

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.

Journal of medicinal chemistry • Vol. 63, Issue 24 • 2020
PMID: 33314938DOI: 10.1021/acs.jmedchem.0c01588

Documentation

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact